92
Participants
Start Date
July 30, 2020
Primary Completion Date
April 22, 2024
Study Completion Date
April 22, 2024
Dexmedetomidine
Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
Propofol
Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
Fentanyl
Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
Peripheral Nerve Stimulation
Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
Placebo
Crystalloid IV solution will be infused, with no active drug.
University of Pittsburgh Medical Center, Pittsburgh
National Institute of General Medical Sciences (NIGMS)
NIH
Keith M Vogt
OTHER